Psychiatry Research: Neuroimaging
Volume 164, Issue 2 , Pages 143-153 , 30 November 2008

Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18

  • Igor Yakushev

      Affiliations

    • Department of Nuclear Medicine, University of Mainz, Mainz, Germany
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, University of Mainz, Langenbeckstr. 1, 55101 Mainz, Germany. Tel.: +49 6131 17 6739; fax: +49 6131 17 2386.
    • ,
  • Christian Landvogt

      Affiliations

    • Department of Nuclear Medicine, University of Mainz, Mainz, Germany
    • ,
  • Hans-Georg Buchholz

      Affiliations

    • Department of Nuclear Medicine, University of Mainz, Mainz, Germany
    • ,
  • Andreas Fellgiebel

      Affiliations

    • Department of Psychiatry, University of Mainz, Mainz, Germany
    • ,
  • Alexander Hammers

      Affiliations

    • Department of Clinical Neuroscience, Division of Neurosciences and Mental Health, Imperial College, London, UK
    • ,
  • Armin Scheurich

      Affiliations

    • Department of Psychiatry, University of Mainz, Mainz, Germany
    • ,
  • Irene Schmidtmann

      Affiliations

    • Department of Nuclear Medicine, University of Munich (LMU), Munich, Germany
    • ,
  • Alexander Gerhard

      Affiliations

    • Department of Psychiatry, University of Mainz, Mainz, Germany
    • Department of Clinical Neuroscience, Division of Neurosciences and Mental Health, Imperial College, London, UK
    • ,
  • Mathias Schreckenberger

      Affiliations

    • Department of Nuclear Medicine, University of Mainz, Mainz, Germany
    • ,
  • Peter Bartenstein

      Affiliations

    • Department of Nuclear Medicine, University of Munich (LMU), Munich, Germany

Received 1 March 2007 ,Revised 1 August 2007 ,Accepted 12 November 2007.

References 

  1. Aguirre GK, Zarahn E, D'Esposito M. The inferential impact of global signal covariates in functional neuroimaging analyses. NeuroImage. 1998;8:302–306
  2. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology. 2005;62:1728–1733
  3. Andersson JL. How to estimate global activity independent of changes in local activity. NeuroImage. 1997;6:237–244
  4. Bai J, Hashimoto J, Ogawa K, Kubo A, Fukunaga A, Onozuka S, et al. Influence of photon scattering and attenuation on ROI analysis in brain perfusion single-photon emission tomographic imaging of normal subjects. Annals of Nuclear Medicine. 2005;19:567–572
  5. Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mosch D, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. Journal of Nuclear Medicine. 1997;38:1095–1101
  6. Bartenstein P, Asenbaum S, Catafau A, Halldin C, Pilowski L, Pupi A, et al. European Association of Nuclear Medicine. European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29:BP43–BP48
  7. Bittner D, Gron G, Schirrmeister H, Reske SN, Riepe MW. [18F]FDG-PET in patients with Alzheimer's disease: marker of disease spread. Dementia and Geriatric Cognitive Disorders. 2005;19:24–30
  8. Bokde AL, Teipel SJ, Drzezga A, Thissen J, Bartenstein P, Dong W, et al. Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 2005;20:352–357
  9. Braak H, Braak E. Alzheimer's disease affects limbic nuclei of the thalamus. Acta Neuropathologica. 1991;81:261–268
  10. Buchert R, Wilke F, Chakrabarti B, Martin B, Brenner W, Mester J, et al. Adjusted scaling of 18F-FDG positron emission tomography images for statistical evaluation in patients with suspected Alzheimer's disease. Journal of Neuroimaging. 2005;15:348–355
  11. Chen WP, Matsunari I, Noda A, Yanase D, Yajima K, Takeda N, et al. Rapid scanning protocol for brain (18)F-FDG PET: a validation study. Journal of Nuclear Medicine. 2005;46:1633–1641
  12. Drzezga A, Arnold S, Minoshima S, Noachtar S, Szecsi J, Winkler P, et al. 18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. Journal of Nuclear Medicine. 1999;40:737–746
  13. Drzezga A, Riemenschneider M, Strassner B, Grimmer T, Peller M, Knoll A, et al. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology. 2005;64:102–107
  14. Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, et al. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry. 2004;56:279–283
  15. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Experimental Neurology. 2005;191:S95–S103
  16. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter 18F-FDG PET. Neuroimage. 2002;17:302–316
  17. Hosaka K, Ishii K, Sakamoto S, Sadato N, Fukuda H, Kato T, et al. Validation of anatomical standardization of FDG PET images of normal brain: comparison of SPM and NEUROSTAT. European Journal of Nuclear Medicine and Molecular Imaging. 2005;32:92–97
  18. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. Journal of Nuclear Medicine. 1997;38:925–928
  19. Ishii K, Imamura T, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology. 1998;51:125–130
  20. Ishii K, Yamaji S, Mori E. Cerebellar metabolic reduction in Alzheimer's disease and data normalization. Journal of Nuclear Medicine. 1998;39:375–376(Letter)
  21. Ishii K, Sasaki M, Matsui M, Sakamoto S, Yamaji S, Hayashi N, et al. A diagnostic method for suspected Alzheimer's disease using H(2)15O positron emission tomography perfusion Z score. Neuroradiology. 2000;42:787–794
  22. Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. Journal of Nuclear Medicine. 2001;42:548–557
  23. Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Annals of Neurology. 2006;59:673–681
  24. Kalpouzos G, Eustache F, de la Sayette V, Viader F, Chetelat G, Desgranges B. Working memory and 18F-FDG-PET dissociate early and late onset Alzheimer disease patients. Journal of Neurology. 2005;252:548–558
  25. Kalter N, Feinberg M, Carroll BJ. Inferential statistical methods for strengthening the interpretation of laboratory test results. Psychiatry Research. 1983;10:207–216
  26. Kasama S, Tachibana H, Kawabata K, Yoshikawa H. Cerebral blood flow in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease according to three-dimensional stereotactic surface projection imaging. Dementia and Geriatric Cognitive Disorders. 2005;19:266–275
  27. Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC. 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis. Journal of Cerebral Blood Flow and Metabolism. 2006;26:1213–1221
  28. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain. 2005;128:1790–1801
  29. Lee DY, Choo IH, Jhoo JH, Kim KW, Youn JC, Lee DS, et al. Frontal dysfunction underlies depressive syndrome in Alzheimer disease: a FDG-PET study. American Journal of Geriatric Psychiatry. 2006;14:625–628
  30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944
  31. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. Journal of Computer Assisted Tomography. 1995;19:541–547
  32. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine. 1995;36:1238–1248
  33. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Annals of Neurology. 1997;42:85–94
  34. Mosconi L, Nacmias B, Sorbi S, De Cristofaro MT, Fayazz M, Tedde A, et al. Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry. 2004;75:370–376
  35. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology. 2004;63:2332–2340
  36. Naidich TP, Valavanis AG, Kubik S. Anatomic relationships along the low-middle convexity: Part I—Normal specimens and magnetic resonance imaging. Neurosurgery. 1995;36:517–532
  37. Pearson RC, Esiri MM, Hiorns RW, Wilcock GK, Powell TP. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:4531–4534
  38. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Archives of Neurology. 2001;58:1985–1992
  39. Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, et al. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. Journal of Neurological Sciences. 2002;200:27–32
  40. Santens P, De Bleecker J, Goethals P, Strijckmans K, Lemahieu I, Slegers G, et al. Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-d-glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. European Neurology. 2001;45:19–27
  41. Soonawala D, Amin T, Ebmeier KP, Steele JD, Dougall NJ, Best J, et al. Statistical parametric mapping of (99 m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. NeuroImage. 2002;17:1193–1202
  42. Stamatakis EA, Glabus MF, Wyper DJ, Barnes A, Wilson JT. Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: A simulation study. Neuroimage. 1999;10:397–407
  43. Steinmetz H, Furst G, Freund HJ. Variation of perisylvian and calcarine anatomic landmarks within stereotaxic proportional coordinates. American Journal of Neuroradiology. 1990;11:1123–1130
  44. Teipel SJ, Willoch F, Ishii K, Burger K, Drzezga A, Engel R, et al. Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease. Neurobiology of Aging. 2006;27:681–690
  45. Wang GJ, Volkow ND, Wolf AP, Brodie JD, Hitzemann RJ. Intersubject variability of brain glucose metabolic measurements in young normal males. Journal of Nuclear Medicine. 1994;35:1457–1466
  46. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Transactions on Nuclear Science. 2000;47:1587–1594
  47. Yetkin FZ, Papke RA, Mark LP, Daniels DL, Mueller WM, Haughton VM. Location of the sensorimotor cortex: functional and conventional MR compared. American Journal of Neuroradiology. 1995;16:2109–2113
  48. Zaidi H, Montandon ML, Slosman DO. Attenuation compensation in cerebral 3D PET: effect of the attenuation map on absolute and relative quantitation. European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:52–63

PII: S0925-4927(07)00229-6

doi: 10.1016/j.pscychresns.2007.11.004

Psychiatry Research: Neuroimaging
Volume 164, Issue 2 , Pages 143-153 , 30 November 2008

Article Tools

* Image Usage & Resolution